India Pharma Outlook Team | Monday, 05 October 2026
Cancer care races forward on multiple tracks. Blood draws promise earlier detection of deadly tumors, while drug combinations aim to hit cancers harder than ever before.
Abbott launches a new blood test for colorectal cancer screening, Grail edges closer to landmark FDA approval for its multi-cancer blood test, and AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up to test a powerful drug combination.
These three moves reshape the field today. Yet insurance coverage stands as the decisive gatekeeper.
Science advances on blood-based early detection and combination therapy at the same time, but payers decide how quickly patients actually benefit from either breakthrough.
Abbott launches SimpleScreen CRC, an FDA-approved blood test that detects circulating cell-free DNA signals linked to colorectal cancer. The company targets adults 45 and older at average risk who decline or skip preferred stool-based or visual tests.
Colorectal cancer ranks as the second-leading cause of cancer-related death in the United States, and as many as 60 million Americans remain due for recommended screening.
Key performance data from the PREEMPT CRC study of more than 48,000 average-risk adults show:
The test detects roughly eight in 10 colorectal cancers and returns negative results for nine in 10 people without the disease or advanced lesions. Medicare covers SimpleScreen CRC with no out-of-pocket costs for eligible Part B patients. Abbott pairs the launch with patient navigation support, including home blood draws and reminders.
Grail’s Galleri multi-cancer early detection test nears a major milestone after an FDA advisory panel concludes its potential benefits outweigh risks. Analysts expect agency approval in the coming months. Galleri detects signals for more than 50 cancer types and identifies the likely origin with 93.4 per cent accuracy.
Also Read: Building Scalable MedTech Ecosystem for India's Healthcare Future
AstraZeneca, Daiichi Sankyo, and Summit Therapeutics launch a clinical collaboration that pairs Datroway (datopotamab deruxtecan), a TROP2-directed antibody-drug conjugate, with Summit’s ivonescimab, a bispecific antibody that combines PD-1 immunotherapy and VEGF inhibition.
The companies start with a Phase III trial in previously untreated triple-negative breast cancer and plan to explore the combination in lung and other breast tumors. Datroway already holds approval in multiple countries for certain patients with triple-negative breast cancer, HR-positive/HER2-negative breast cancer, and EGFR-mutated non-small cell lung cancer.
Ivonescimab holds approval for certain non-small cell lung cancer patients in China, with a U.S. Biologics License Application under FDA review. Each company supplies its own medicine and retains commercial rights while sharing trial costs.
Insurance coverage remains the critical bottleneck. No multi-cancer early detection test currently qualifies for broad Medicare or private insurance payment. FDA approval could open Medicare eligibility starting in 2028 under recent U.S. law. Private insurers would likely follow if the U.S. Preventive Services Task Force recommends the tests.
Analysts project a potential USD 60 billion annual U.S. market by 2030 if 120 million adults aged 50 and older take a USD 500 test each year.
Only five cancers currently have established U.S. preventive screening guidelines. Multi-cancer blood tests aim to close that gap, yet questions persist about whether they ultimately reduce cancer deaths.
Doctors note that positive results trigger costly follow-up testing and that early tumors shed limited signals into the blood. These three moves; Abbott’s colorectal blood test launch, Grail’s advancing Galleri path, and the AstraZeneca-Daiichi-Summit drug combination, push cancer care toward earlier detection and more aggressive treatment.
.jpg)
